June 1, 2023
September 11, 2023
Case Report: MDPI pNET

The article "Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support" describes a case study of a patient with metastatic pancreatic neuroendocrine carcinoma (pNET) that was resistant to standard chemotherapy treatments. The patient underwent liquid biopsy testing, which identified genomic mutations in the tumor DNA that were potentially targetable by available drugs. A computational decision support tool, Genomate, was then used to analyze the genomic data and identify personalized treatment options based on the patient's individual molecular profile.

Key Takeaways:

Read the entire article here.

Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I.
Diagnostics (Basel). 2021 Oct 7;11(10):1850. doi: 10.3390/diagnostics11101850. PMID: 34679548; PMCID: PMC8534772.